Table 2.
Orbital decompression and Rituximab treatment details of the two patients.
| Patient number | Patient 1 | Patient 2 |
|---|---|---|
| Reason for orbital decompression | DON, no improvement after intravenous MPS | Relapse and DON developed after intravenous MPS and orbital radiotherapy |
| Total dose of MPS before orbital decompression | 3.5g | 8.5g |
| Duration of MPS use before orbital decompression | 7 weeks | 23 weeks |
| Orbital decompression (time relative to DON diagnosis) | At 7 weeks | At 1 week |
| Immunosuppressive treatments after orbital decompression | Intravenous MPS 0.5g and oral MPS | None (prior to RTX) |
| RTX therapy (time related to orbital decompression) | At 52 days | At 4 days |
| RTX therapy (time related to diagnosisi) | 5 months | 8 months |
| Reason for RTX therapy | Failure of glucocorticoids treatment | MPS dose exceeded 8g |
| RTX dose | 500mg only once | 500mg only once |
| Immunosuppressive treatments after RTX | Oral MPS | Oral MPS |
DON, dysthyroid optic neuropathy; MPS, methylprednisolone; RTX, rituximab.